PR Newswire Clinical TrialsOriginal article
ПОЛОЖИТЕЛЬНАЯ ОЦЕНКА CHMP ПОДДЕРЖИВАЕТ БОЛЕЕ ШИРОКОЕ ПРИМЕНЕНИЕ ПРЕПАРАТА REPATHA® КОМПАНИИ AMGEN ДЛЯ СНИЖЕНИЯ РИСКА ПЕРВОГО ИНФАРКТА ИЛИ ИНСУЛЬТА
RegulatorypositiveRepathaPositive
AI Analysis
Summary
Amgen's Repatha received a positive CHMP assessment supporting expanded use for reducing the risk of first myocardial infarction and stroke in cardiovascular patients. Repatha is the only PCSK9 inhibitor with Phase 3 evidence demonstrating efficacy in reducing first MI and stroke risk.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
CHMP positive assessment supporting broader use of Repatha for reducing risk of first heart attack or stroke
Importance:7/10
Sentiment:
0.75
PCSK9_inhibitorcardiovascularregulatory_approvalCHMP
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 31, 2026 7:57 PM